130 related articles for article (PubMed ID: 38744302)
1. The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort study.
Lee MS; Chiou SY; Hsu FC; Lin HY; Li CY; Hung SK; Yu BH; Wu CC; Chen LC; Chew CH; Chiou WY
Hum Vaccin Immunother; 2024 Dec; 20(1):2350093. PubMed ID: 38744302
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study.
Chiou WY; Hung SK; Lin HY; Chen LC; Hsu FC; Tsai SJ; Yu BH; Lee MS; Li CY
Medicine (Baltimore); 2019 Dec; 98(50):e18380. PubMed ID: 31852152
[TBL] [Abstract][Full Text] [Related]
4. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
[TBL] [Abstract][Full Text] [Related]
5. Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study.
Li CY; Chen LC; Lin HY; Lee MS; Hung SK; Lai CL; Huang LW; Yu BH; Hsu FC; Chiou WY
Cancer; 2021 Jan; 127(1):124-136. PubMed ID: 32997342
[TBL] [Abstract][Full Text] [Related]
6. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
8. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
10. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up.
Hedlund J; Christenson B; Lundbergh P; Ortqvist A
Vaccine; 2003 Sep; 21(25-26):3906-11. PubMed ID: 12922125
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
12. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
[TBL] [Abstract][Full Text] [Related]
13. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan--a representative population-based comparative study.
Chang YC; Chou YJ; Liu JY; Yeh TF; Huang N
J Infect; 2012 Sep; 65(3):231-8. PubMed ID: 22561486
[TBL] [Abstract][Full Text] [Related]
14. Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan.
Yamana H; Ono S; Michihata N; Uemura K; Jo T; Yasunaga H
Clin Microbiol Infect; 2023 Jul; 29(7):904-910. PubMed ID: 37044276
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
[No Abstract] [Full Text] [Related]
16. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
